This finding aligns with published results from a review indicating that baseline Ki-67 expression below 30% consistently correlates with an increased risk of HER2+ recurrence, while higher baseline Ki-67 expression is associated with a reduced recurrence risk of HER2+ BC across various treatment settings [13]. The gene discussed is ERBB2; the disease is breast cancer.